Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bazlitoran |
Synonyms | |
Therapy Description |
Bazlitoran (IMO-8400) is a TLR 7, 8 and 9 antagonist, which leads to decreased growth of tumors with activated TLR signaling (Cancer Res October 1, 2014 74:2570, PMID: 27876460). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bazlitoran | IMO-8400 | Bazlitoran (IMO-8400) is a TLR 7, 8 and 9 antagonist, which leads to decreased growth of tumors with activated TLR signaling (Cancer Res October 1, 2014 74:2570, PMID: 27876460). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02092909 | Phase Ib/II | Bazlitoran | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401) | Terminated | USA | 0 |
NCT02252146 | Phase Ib/II | Bazlitoran | Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation | Completed | USA | 0 |